

According to (EC) No 1907/2006 (REACH) and 1272/2008 (CLP)

### EN

CROTAMITONUM

PAGE 1 OF 9
Publication: 08/03/2022
Revision: 18/09/2024
Version: 01

.1 Product identifier		
Product name:	Crotamiton	
	Crotamitonum	
	Crotamiton	
	Crotamiton	
	Crotamiton	
N° CAS:	483-63-6	
N° EC:	207-596-3	
.2 Relevant identified uses of the	ne substance/mixture and uses adv	ised against
Identified uses:	Active Pharmaceutical Ingredi	ent or Excipient.
.3 Details of the supplier of the	safety data sheet	
Company:	Magis-Pharma NV	
	Neerlandweg 24	
	2610 Wilrijk	
	Belgium	
Telephone:	(+32) (0)3 457 11 76	
Email:	info@magis-pharma.be	
Web page:	www.magis-pharma.be	
.4 Emergency telephone number	er	
Public utility foundation:	Belgisch Antigifcentrum	Centre Antipoisons Belge
Telephone:	(+32) (0)70 245 245	(Service 24/7)
Web page:	www.antigifcentrum.be	www.centreantipoisons.be
ION 2: HAZARDS IDENTIFICATIO	DN	
.1 Classification of the substand	ce/mixture	
Classification according to (E	C) n° 1272/2008	
Acute Tox. 4	H302	
Skin Irr. 2	H315	
Skin Sens. 1	H317	
Eye Irr. 2	H319	
.2 Label elements		
Labelling according to (EC) n°	1272/2008	
Hazard pictogram(s):	$\wedge$	



According to (EC) No 1907/2006 (REACH) and 1272/2008 (CLP)

### EN

CROTAMITONUM

PAGE 2 OF 9
Publication: 08/03/2022
Revision: 18/09/2024
Version: 01

Signal word(s):	Attention
Hazard statements:	
H302	Harmful if swallowed.
H315	Causes skin irritation.
H317	May cause an allergic skin reaction.
H319	Causes serious eye irritation.
Precautionary statements:	
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P301+312+330	IF SWALLOWED: Call a POISON CENTER or doctor/physician if you feel unwell.
P302+352	IF ON SKIN: Wash with soap and water.
P305+338+351	IF IN EYES: Rinse continuously with water for several minutes. Remove contact lenses if present and easy to do. Continue rinsing.
P308+313	IF exposed or concerned: Get medical advice/attention.
Additional applicable label elements:	Not applicable.
2.3 Other hazards	
Not available.	
SECTION 3: COMPOSITION/INFORM	ATION ON INGREDIENTS
3.1 Substances	
Product name:	Crotamiton
IUPAC name:	N-Ethyl-N-(2-methylphenyl)but-2-enamide

IUPAC name:	N-Ethyl-N-(2-methylphenyl)but-2-enamide
Synonyms:	Eurax
	Crotalgin
	Veteusan
N° CAS:	483-63-6
N° EC:	207-596-3
Molecular Formula:	C <sub>13</sub> H <sub>17</sub> NO
Content:	Sum of the (E)- and (Z)-isomers: 96.0 per cent to 102.0 per cent.
	(Z)-isomer: maximum 15.0 per cent.

#### 3.2 Mixtures

Not applicable.

# SECTION 4: FIRST AID MEASURES

### 4.1 Description of first aid measures

After inhalation:

Remove to a fresh air area and get medical attention if necessary.



According to (EC) No 1907/2006 (REACH) and 1272/2008 (CLP)

### CROTAMITONUM

PAGE 3 OF 9 Publication: 08/03/2022 Revision: 18/09/2024 Version: 01

After skin contact:	Remove all contaminated clothing and flush skin, hair etc. with running water.	
After eye contact:	Immediately flush eyes with plenty of water and get medical attention.	
After ingestion:	Get medical attention.	
4.2 Most important symptoms and	effects, both acute and delayed	
Not available.		
4.3 Indication of any immediate me	dical attention and special treatment needed	
Not available.		
ECTION 5: FIREFIGHTING MEASURES		
5.1 Extinguishing media		
Suitable extinguishing media:	Foam, dry chemical powder, CO <sub>2</sub> , water.	
Unsuitable extinguishing media:	Heavy water stream.	
5.2 Special hazards arising from the	substance/mixture	
Not available.		
5.3 Advice for firefighters		
Surrounding fires:	General fire hazards: combustible.	
	Fire incompatibility: Avoid contamination.	
Protection against fire:	In the event of a fire, wear full protective clothing, chemical	
	protective goggles, gloves and appropriate respirator containing	
	type A filter of sufficient capacity.	
Hazardous combustion products:	Incomplete combustion will generate poisonous CO, CO <sub>2</sub> , and oth toxic gases.	

#### 6.1 Personal precautions, protective equipment and emergency procedures

#### For non-emergency personnel

Remove all sources of ignition. Ventilate the area where the leak or spill occurred. Wear appropriate personal protective equipment as specified in section 8, and isolate the hazard area. Keep unnecessary and unprotected personnel from entering.

#### For emergency responders

Remove all sources of ignition. Ventilate the area where the leak or spill occurred. Wear appropriate personal protective equipment as specified in section 8, and isolate the hazard area. Keep unnecessary and unprotected personnel from entering.

#### **6.2** Environmental precautions

Do not discharge into sewer or waterways.

#### 6.3 Methods and material for containment and cleaning up

Carefully sweep up material into an appropriate container and save for reclamation or disposal.



According to (EC) No 1907/2006 (REACH) and 1272/2008 (CLP)

## **CROTAMITONUM**

PAGE 4 OF 9
Publication: 08/03/2022
Revision: 18/09/2024
Version: 01

6.4 Reference to other sections		
Not available.		
TION 7: HANDLING AND STORA	GE	
7.1 Precautions for safe handling	g	
Precautions for safe handling	:	Use in a well ventilated area. When handling do not eat, drink or smoke.
Personal protection:		Wear protective equipment. Avoid personal contact including inhalation.
Technical protective measure	s:	Not available.
Handling:		Not available.
7.2 Conditions for safe storage, i	ncluding any inc	
Storage:		Store in a well closed container.
Conditions for safe storage, ir incompatibilities:	ncluding any	Temperature should not be more than 40 °C. Relative humidity should not be more than 75 %.
Storage – away from:		Store protected from light.
7.3 Specific end use(s) Active Pharmaceutical Ingred	ient or Excipient	
7.3 Specific end use(s) Active Pharmaceutical Ingred		
7.3 Specific end use(s) Active Pharmaceutical Ingred		
7.3 Specific end use(s) Active Pharmaceutical Ingred CTION 8: EXPOSURE CONTROLS/F 8.1 Control parameters		
7.3 Specific end use(s) Active Pharmaceutical Ingred		
7.3 Specific end use(s) Active Pharmaceutical Ingred CTION 8: EXPOSURE CONTROLS/F 8.1 Control parameters		
7.3 Specific end use(s) Active Pharmaceutical Ingred CTION 8: EXPOSURE CONTROLS/F 8.1 Control parameters Not available.	PERSONAL PROT	
<ul> <li>7.3 Specific end use(s) <ul> <li>Active Pharmaceutical Ingred</li> </ul> </li> <li>TION 8: EXPOSURE CONTROLS/F</li> <li>8.1 Control parameters <ul> <li>Not available.</li> </ul> </li> <li>8.2 Exposure controls <ul> <li>Appropriate engineering con</li> <li>Ventilation system: A system</li> </ul> </li> </ul>	PERSONAL PROT trol of local and/or g ation is generally	ECTION general exhaust is recommended to keep employee exposures as low a preferred because it can control the emissions of the contaminant at
<ul> <li>7.3 Specific end use(s) <ul> <li>Active Pharmaceutical Ingred</li> </ul> </li> <li>CTION 8: EXPOSURE CONTROLS/F</li> <li>8.1 Control parameters <ul> <li>Not available.</li> </ul> </li> <li>8.2 Exposure controls <ul> <li>Appropriate engineering con</li> <li>Ventilation system: A system</li> <li>possible. Local exhaust ventiliation</li> </ul></li></ul>	PERSONAL PROT trol of local and/or g ation is generally of it into the gen	ECTION general exhaust is recommended to keep employee exposures as low a preferred because it can control the emissions of the contaminant at
<ul> <li>7.3 Specific end use(s) <ul> <li>Active Pharmaceutical Ingred</li> </ul> </li> <li>TION 8: EXPOSURE CONTROLS/F</li> <li>8.1 Control parameters <ul> <li>Not available.</li> </ul> </li> <li>8.2 Exposure controls <ul> <li>Appropriate engineering con</li> <li>Ventilation system: A system possible. Local exhaust ventila source, preventing dispersion</li> </ul></li></ul>	ERSONAL PROT trol of local and/or g ation is generally of it into the gen res Use chemic	ECTION general exhaust is recommended to keep employee exposures as low a preferred because it can control the emissions of the contaminant at
<ul> <li>7.3 Specific end use(s) <ul> <li>Active Pharmaceutical Ingred</li> </ul> </li> <li>TION 8: EXPOSURE CONTROLS/F</li> <li>8.1 Control parameters <ul> <li>Not available.</li> </ul> </li> <li>8.2 Exposure controls <ul> <li>Appropriate engineering con</li> <li>Ventilation system: A system</li> <li>possible. Local exhaust ventilis</li> <li>source, preventing dispersion</li> <li>Individual protection measure</li> </ul></li></ul>	errol of local and/or g ation is generally of it into the gen res Use chemic Provide an Wear impe	ECTION general exhaust is recommended to keep employee exposures as low a preferred because it can control the emissions of the contaminant at neral work area.
<ul> <li>7.3 Specific end use(s) <ul> <li>Active Pharmaceutical Ingred</li> </ul> </li> <li>CTION 8: EXPOSURE CONTROLS/F</li> <li>8.1 Control parameters <ul> <li>Not available.</li> </ul> </li> <li>8.2 Exposure controls <ul> <li>Appropriate engineering con</li> <li>Ventilation system: A system</li> <li>possible. Local exhaust ventils source, preventing dispersion</li> <li>Individual protection measure</li> <li>Eye/face protection:</li> </ul> </li> </ul>	errol of local and/or g ation is generally of it into the gen res Use chemic Provide an Wear impe	ECTION general exhaust is recommended to keep employee exposures as low a preferred because it can control the emissions of the contaminant at neral work area. cal safety goggles and/or a full face shield where splashing is possible. eye wash fountain and quick-drench facilities in the work area. ervious protective clothing, including boots, gloves, lab coat, apron or as appropriate, to prevent skin contact.



### According to (EC) No 1907/2006 (REACH) and 1272/2008 (CLP)

### EN

## **CROTAMITONUM**

PAGE 5 OF 9 Publication: 08/03/2022 Revision: 18/09/2024 Version: 01

Thermal hazards:	Not determined.
Environmental exposure contro	bl
Not available.	
ON 9: PHYSICAL AND CHEMICAL	PROPERTIES
1 Information on basic physical a	nd chemical properties
Appearance:	Colourless or pale yellow, oily liquid.
Odour:	Almost odourless.
Odour threshold:	Not available.
pH:	Not available.
Melting/freezing point:	Not available.
Initial boiling point:	Not available.
Boiling range:	Not available.
Flash point:	Not available.
Evaporation rate:	Not available.
Flammability (solid/gas):	Not available.
Upper/lower flammability or explosive limits:	Not available.
Vapour pressure:	Not available.
Vapour density:	Not available.
Relative density:	1.006 to 1.011
Solubility:	Miscible with ethanol (96 per cent). At low temperatures it may partly or complet solidify.
Solubility in water:	Slightly soluble in water.
Partition coefficient (n-octanol/water):	Not available.
Auto-ignition temperature:	Not available.
Decomposition temperature:	Not available.
Viscosity:	Not available.
Explosive properties:	Not available.
Oxidising properties:	Not available.
2 Other information	

#### SECTION 10: STABILITY AND REACTIVITY



According to (EC) No 1907/2006 (REACH) and 1272/2008 (CLP)

### **CROTAMITONUM**

Publication: 08/03/2022 Revision: 18/09/2024 Version: 01

Not available.	
10.2 Chemical stability	
Stable under normal conditions i	n tightly closed containers, protected from light.
10.3 Possibility of hazardous reaction	ons
Hazardous polymerisation: Will r	not occur.
10.4 Conditions to avoid	
Incompatibles. Light (sunlight inc	cluded). Heat.
10.5 Incompatible materials	
Avoid reaction with oxidising age	ents.
10.6 Hazardous decomposition pro	ducts
Not available.	
TION 11: TOXICOLOGICAL INFORM	ATION
11.1 Information on toxicological e	ffects
Acute toxicity:	Oral LD50 (rat): 1 500 mg/kg
	Intraperitoneal LD50 (rat): 318 mg/kg
	Subcutaneous LD50 (rat): 1 630 mg/kg
	Oral LD50 (mouse): 1 600 mg/kg
	Intraperitoneal LD50 (mouse): 395 mg/kg
	Subcutaneous LD50 (mouse) : 1 393 mg/kg
Skin corrosion/irritation:	May cause skin irritation. May be harmful by skin absorption.
Serious eye damage/irritation:	May cause eye irritation.
Respiratory/skin sensitisation:	Sensitisation possible through skin contact.
Germ cell mutagenicity:	Not available.
Carcinogenicity:	Not available.
Reproductive toxicity:	Not available.
Summary of evaluation of the CMR properties:	Not available.
STOT-single exposure:	Not available.
STOT-repeated exposure:	Not available.
Aspiration Hazard:	Not available.
Other:	Not available.
11.2 Additional information on pot	ential adverse human health effects and symptoms
Eye contact:	May cause eye irritation.
Skin contact:	May cause skin irritation. May be harmful by skin absorption.
Inhalation:	May be harmful by inhalation.
	, ,

### EN

PAGE 6 OF 9



### EN

According to (EC) No 1907/2006 (REACH) and 1272/2008 (CLP)

# **CROTAMITONUM**

PAGE 7 OF 9
Publication: 08/03/2022
Revision: 18/09/2024
Version: 01

Ingestion:	May be harmful by ingestion.	
Aspiration:	Not available.	
CTION 12: ECOLOGICAL INFORMAT	ΓΙΟΝ	
12.1 Toxicity		
Not available.		
12.2 Persistence and degradabilit	v	
Persistence: water, air: high.	1	
12.3 Bioaccumulative potential		
Bioaccumulation: low.		
12.4 Mobility in soil		
Mobility: medium.		
12.5 Results of PBT and vPvB assessment		
Not applicable.		
12.6 Other adverse effects		
Do not discharge into sewers o	pr waterways.	
CTION 13: DISPOSAL CONSIDERATI	IONS	
13.1 Waste treatment methods		
	ecovery or recycling, should be managed in an appropriate and approved waste dispos tamination of this product may change the waste management options. State and loca	
disposal regulations may differ	r from federal disposal regulations.	
disposal regulations may differ Dispose of container and unus	r from federal disposal regulations. ed contents in accordance with federal, state and local requirements.	
Dispose of container and unuse	ed contents in accordance with federal, state and local requirements.	
Dispose of container and unuse	ed contents in accordance with federal, state and local requirements.	
Dispose of container and unuse	ed contents in accordance with federal, state and local requirements.	
Dispose of container and unuse CTION 14: TRANSPORT INFORMAT Transport information according t	ed contents in accordance with federal, state and local requirements.	
Dispose of container and unuse CTION 14: TRANSPORT INFORMAT Transport information according to 14.1 UN Number ADR/ RID(Land),IMDG(Sea),	ed contents in accordance with federal, state and local requirements. ION to ADR/RID/IMDG/ICAO/IATA	
Dispose of container and unuse CTION 14: TRANSPORT INFORMAT Transport information according to 14.1 UN Number ADR/ RID(Land),IMDG(Sea), IATA/ICAO (Air) :	ed contents in accordance with federal, state and local requirements. ION to ADR/RID/IMDG/ICAO/IATA	
Dispose of container and unuse CTION 14: TRANSPORT INFORMAT Transport information according to 14.1 UN Number ADR/ RID(Land),IMDG(Sea), IATA/ICAO (Air) : 14.2 UN proper shipping name ADR/ RID(Land),IMDG(Sea),	ed contents in accordance with federal, state and local requirements.	
Dispose of container and unuse CTION 14: TRANSPORT INFORMAT Transport information according to 14.1 UN Number ADR/ RID(Land),IMDG(Sea), IATA/ICAO (Air) : 14.2 UN proper shipping name ADR/ RID(Land),IMDG(Sea), IATA/ICAO (Air) :	ed contents in accordance with federal, state and local requirements.	



### EN

According to (EC) No 1907/2006 (REACH) and 1272/2008 (CLP)

Publication: 08/03/2022

PAGE 8 OF 9

Revision: 18/09/2024

CROTAMITONUM

Version: 01

ADR/ RID(Land),IMDG(Sea), IATA/ICAO (Air) :	Not classified.
14.5 Environmental hazards	
ADR/ RID(Land),IMDG(Sea), IATA/ICAO (Air) :	Not classified.
14.6 Special precautions for user	
Not available.	
14.7 Transport in bulk according t	o annex II of Marpol and the IBC Code
Not available.	
14.8 Additional transport informa	ition
Well closed container, protecte Temperature should not be mo Relative humidity should not be	pre than 40 °C.
SECTION 15: REGULATORY INFORMA	TION
15.1 Safety, health and environme	ental regulations/legislation specific for the substance/mixture
Hazard symbol:	×
Risk phrases:	Not applicable.
Safety phrases:	S36/37/39 Wear suitable protective clothing, gloves and eye/face protection.
15.2 Chemical safety assessment	
A chemical safety assessment h	nas not been carried out.
SECTION 16: OTHER INFORMATION	
16.1 Changes since the previous v	ersion
Not applicable.	
16.2 Abbreviations and acronyms	used
ADR:	European Agreement concerning the International Carriage of Dangerous Goods by Road
CAS:	Chemical Abstracts Service (division of the American Chemical Society)
EC (number):	European Community (number)
ΙΑΤΑ:	International Air Transport Association
ICAO:	International Civil Aviation Organization
ICAO: IMDG:	International Civil Aviation Organization International Maritime Code for Dangerous Goods



# **MATERIAL SAFETY DATA SHEET**

According to (EC) No 1907/2006 (REACH) and 1272/2008 (CLP)

PAGE 9 OF 9

### **CROTAMITONUM**

Publication: 08/03/2022 Revision: 18/09/2024 Version: 01

RID:	Regulations Concerning the International Transport of Dangerous Goods by Rail
STOT:	Specific Target Organ Toxicity
UN (number):	United Nations (number)
vPvB:	very Persistent and very Bioaccumalative
16.3 Key literature reference	es/sources for data
European Chemicals Age	ency.
https://www.echa.europ	pa.eu/web/guest/information-on-chemicals/cl-inventory-database/
16.4 Method of classification	in in case of mixture
Not applicable.	
16.5 Relevant Hazard state	ments and/or precautionary statements
For information on haza	rd and/or precautionary statements refer to section 2 up to and including section 15.
16.6 Training advisement	
Not available.	
16.7 Notice for user(s)	
The information provided in this MSDS has been established in accordance with Commission Regulation (EU) 2015/83 of 28 May 2015, amending Regulation (EC) No 1907/2006 of the European Parliament and of the Council, on the Registration, Evaluation, Authorization and Restriction of Chemicals (REACH), establishing the European Chemical Agency, amending Directive 1999/45/EC and repealing Council Regulation (EC) No 793/93 and Commission Regulation (EC) No 1488/94, as well as Council Directive 76/769/EEC and Directives 91/155/EEC, 93/67/EEC, 93/105/EC are 2000/21/EC of the Commission.	
information has been con NV's knowledge. Howev regarding its accuracy of the use and/or misuse of the use and the u	p provide a brief summary of our knowledge and guidance regarding the use of this material. The propiled from sources considered to be dependable and is accurate to the best of the FRAVE ver, the information is provided without any representation or warranty, expressed or implier correctness. FRAVER NV cannot assume responsibility for adverse events which may occur if this product and expressly disclaims liability for loss, damage and/or expense arising out of o ith the handling, storage, use and/or disposal of this product.
16.8 Department issuing M	SDS
Quality Department	
FRAVER NV	
info@magis-pharma.be	